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Abstract
The presence of stem cell characteristics in glioma cells raises the possibility that mechanisms promoting the maintenance
and self-renewal of tissue specific stem cells have a similar function in tumor cells. Here we characterized human gliomas of
various malignancy grades for the expression of stem cell regulatory proteins. We show that cells in high grade glioma co-
express an array of markers defining neural stem cells (NSCs) and that these proteins can fulfill similar functions in tumor
cells as in NSCs. However, in contrast to NSCs glioma cells co-express neural proteins together with pluripotent stem cell
markers, including the transcription factors Oct4, Sox2, Nanog and Klf4. In line with this finding, in high grade gliomas
mesodermal- and endodermal-specific transcription factors were detected together with neural proteins, a combination of
lineage markers not normally present in the central nervous system. Persistent presence of pluripotent stem cell traits could
only be detected in solid tumors, and observations based on in vitro studies and xenograft transplantations in mice imply
that this presence is dependent on the combined activity of intrinsic and extrinsic regulatory cues. Together these results
demonstrate a general deregulated expression of neural and pluripotent stem cell traits in malignant human gliomas, and
indicate that stem cell regulatory factors may provide significant targets for therapeutic strategies.
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Introduction
The identification of tumor cells with stem cell properties
supports the idea that a subpopulation of cancer cells is responsible
for the initiation, growth and recurrence of tumors. Apparent
similarities with non-transformed stem cells, including high self-
renewal capacity and the ability to generate differentiated progeny
of several cellular lineages, have lead to the proposal that stem cell-
like cancer cells may either originate from adult undifferentiated
stem and progenitor cells or that these properties are being
expressed as an effect of the genetic alterations which drive
tumorigenicity [1]. Regardless, the association of stem cell traits
with cancer pathogenesis motivates a further characterization of
stem cell related signatures in tumors and a better description of
molecular similarities and differences in comparison with non-
transformed stem cells.
Glioma is the most common form of primary tumors of the
central nervous system (CNS) in adults [1]. Based on histopath-
ological traits this type of tumor can be divided into four
malignancy grades (grade I-IV, World Health Organization)
where grade IV tumors, glioblastoma multiforme, are the most
malignant with no curative measures available [1,2,3]. Several
reports have demonstrated that gliomas harbor cells with stem cell-
like features, including the ability to generate progeny of the
neural and glial lineages, as well as, to mediate the recurrence of
tumors [4]. For example, the cell-surface protein CD133 (or
prominin-1), which is expressed by stem cells of the human brain
[5] has also been used to enrich for stem cells in gliomas [4,6,7]
and has been considered as a marker for cells with enhanced
tumorigenicity [4,6,7]. The HMG-box transcription factor Sox2
and the bHLH protein Olig2 constitute additional examples of
factors commonly expressed by glioma cells and stem cells of the
embryonic and adult brain [8,9,10]. Interestingly, both Sox2 and
Olig2 have been ascribed important roles in maintaining self-
renewing stem cells in the CNS [10,11] and this activity appears,
at least in part, to be conserved in gliomas [8,10,12,13]. For
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[12] of human glioma cells and reduces their tumor-inducing
potential when transplanted into the rodent brain [8]. Hence,
transcription factors with key regulatory roles in non-transformed
stem cells are both expressed and possess similar vital functions in
the maintenance of lineage-related stem and progenitor cells in
gliomas.
However, the gene expression profile in gliomas may not
necessarily mirror its cell of origin. For example, the transcription
factor Oct4, which has an important role in maintaining
embryonic stem (ES) cells in a self-renewing and pluripotent state
[14], is not expressed in the adult brain but can be detected in high
grade gliomas [15]. Moreover, downstream targets of Oct4 have
been reported to be more frequently over-expressed in high grade
gliomas, compared with lower grade tumors [16]. In the adult
mice misexpression of Oct4 in epithelial tissues results in dysplasia
caused by a block in progenitor differentiation [17]. Thus, the
reactivation of stem cell genes, such as Oct4, may contribute to the
enhanced malignancy of high grade gliomas.
It is interesting that several transcriptional networks with vital
functions in neural and other stem cell populations appear to be
expressed in gliomas [8,10,16]. Their necessity for the mainte-
nance of self-renewing stem and progenitor cells, raises the
possibility that these proteins, independently of genetic alterations,
may constitute relevant targets for therapeutic strategies aiming to
prevent growth and recurrence of tumors [18]. However, to
realize this idea we first need to characterize the combined
expression of stem cell regulatory components in gliomas and
understand how these proteins function to control growth and
survival of cancer cells. Here we examined human gliomas for the
expression of transcription factors with key roles in controlling the
self-renewing undifferentiated state of ES-cells and NSCs. We
show that stem cell traits normally present in NSCs are aberrantly
co-expressed with pluripotent stem cell markers in high grade
gliomas. Together our findings indicate that transcriptional
mechanisms regulating normal stem cells may contribute to the
malignancy of glioma cells.
Results
Conserved features between glioma and neural stem
cells
SoxB1 (Sox1, Sox2 and Sox3) transcription factors are co-
expressed by the majority of all NSCs both in the developing and
adult CNS, and constitute important regulators of NSC mainte-
nance [9,19]. To define molecular similarities and differences
between non-transformed CNS stem cells and glioma cells, we
characterized SoxB1 gene expression both at the mRNA and
protein level in human gliomas of different malignancy grades. In
grade IV tumors, verified by hematoxylin and eosin staining (Fig.
S1), the domains of Sox1, Sox2 and Sox3 mRNA expression
overlapped extensively (Fig. 1A–C). Moreover, most cells expres-
sing Sox2 protein also showed immunoreactivity with antibodies
specific for Sox1 or Sox3 protein (Fig. 1D,E; and Fig. S2). The
proportion of cells expressing Sox2 was similar in grade II – IV
tumors (Fig. 1F) in which Sox2 could be detected in approximately
Figure 1. Expression of neural stem cell properties in human glioma. (A–C) Serial sections of a grade IV glioma show overlapping expression
of Sox1 (A), Sox2 (B) and Sox3 (C) mRNA. (D,E) Most Sox2
+ cells co-express Sox1 (D) and Sox3 (E) proteins in grade IV tumors. (F) Gliomas of grade II-IV
harbor a larger proportion of Sox2
+ cells in comparison with the grade I tumors. (G,H) Sox2 expression overlaps extensively with the neural progenitor
marker Nestin (H) and with the majority of cells expressing the cell cycle marker Ki67 (G). (I) Most cells expressing the neuronal protein Neurofilament-
1 (NF1) express no or only low levels of Sox2. (J) Representative section of grade IV tumor stained with hematoxylin and eosin (H&E) (J). Data are
represented as mean +/2 SEM. *= p,0.05, **= p,0.01, ***= p,0.001, Student’s t-test. Scale bars; 200 mm in A–C, 20 mmi nE ;2 0mmi nJ .
doi:10.1371/journal.pone.0018454.g001
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only be detected in less than 20% of the cells (Fig. 1F). Sox3
followed the same expression pattern as Sox2 in all tumor samples
examined. However, we were unable to detect any significant
expression of Sox1 mRNA or protein in grade I – III tumors (data
not shown), and co-expression of Sox1-3 was mainly found in
grade IV tumors. In the CNS, the expression of Sox1-3 is confined
to self-renewing precursor cells, but is generally downregulated as
cells exit the cell cycle and start to differentiate into neurons or glia
[9,19]. In keeping with this, Sox2 could be detected in the vast
majority of cells in grade IV tumors expressing the proliferation
marker Ki67 (Fig. 1G) and almost all Sox2
+ cells co-expressed the
neural progenitor marker Nestin ($95%) (Fig. 1H). In addition,
the majority of cells expressing markers for differentiated neurons,
such as Neurofilament-1 (NF1) (Fig. 1I) were Sox2-negative. Thus,
similar to the healthy CNS undifferentiated proliferating cells in
high grade gliomas co-express Sox1-3 transcription factors.
A negative form of Sox3 promotes glioma cells to exit
the cell cycle
Gain-of-function experiments have previously demonstrated
that Sox1-3 maintain neural cells as self-renewing progenitors
[9,19], while dominant-negative versions of these proteins have the
opposite functions and cause NSCs to exit the cell cycle and
commit to differentiation [9,19,20]. To examine if Sox3 has
a similar regulatory capacity in glioma cells as in NSCs, we
transfected primary cultures derived from human grade IV
gliomas with vectors expressing either full-length Sox3, a dominant
negative version of Sox3 (Sox3EnR-Myc) [9] or enhanced GFP
(EGFP). Many cells misexpressing a Myc-tagged version of Sox3
incorporated the thymidine analogue bromodeoxyuridine (BrdU)
24 hours after transfection (Fig. 2A,J) and expressed the cell cycle
marker Ki67 (Fig. 2B,K) and the NSC markers Sox1 and Nestin
48 hours after transfection (Fig. 2C,L; and data not shown). In
contrast, misexpression of Sox3EnR-Myc for 24 hours, promoted
cells to leave the cell cycle, as indicated by the decrease in BrdU
incorporation (Fig. 2D,J) and the reduction of cells positive for
Ki67 (Fig 2E,K). Misexpression of Sox3EnR-Myc also increased the
number of cells that downregulated the expression of the neural
progenitor marker Nestin (Fig. 2F,L). Thus, as in the developing
CNS [9] Sox3 has the capacity to maintain glioma cells in an
undifferentiated and proliferating state, whereas active repression
of Sox3 target genes causes cells to exit the cell cycle.
Co-expression of Sox2, Oct4, Nanog and Klf4 in
high-grade gliomas
Examination of publicly available gene expression data sets
indicate that high grade human gliomas and ES-cells share
similarities at the molecular level [16]. Several of the features
associated with ES-cells, such as pluripotency, extensive self-
renewing capacity and their gene expression profile, have been
ascribed a transcriptional unit consisting of Sox2, Oct4 and Nanog
[21]. Interestingly, significant levels of Nanog and Oct4 mRNA
could be detected in grade IV tumors (Fig. 3D,H). Using specific
antibodies against Sox2, Oct4 and Nanog (Fig. S3) we found an
extensive overlap in their expression pattern and many grade IV
tumor cells (Fig. S4) expressing Nanog or Oct4 protein co-
expressed Sox2 (Fig. 3B,F). The combinatorial expression of Sox2,
Nanog and Oct4 increased with increasing grades of malignancy.
While the proportion of Nanog
+/Sox2
+ cells was similar in a grade
II and a grade IV tumor (Fig. 3A–C), the amount of Sox2
+ cells
expressing Oct4 was increased from below 5% in grade II gliomas
to above 50% in grade IV tumors (Fig. 3E–G). Most Nanog
+ and
Oct4
+ cells expressed the cell cycle marker Ki67 (Fig. 3I,J) and the
NSC markers Nestin and Sox1 (Fig. 3K,L; and data not shown).
Moreover, the transcription factor Klf4, which has been shown to
cooperate with Sox2 and Oct4 in target gene activation in
pluripotent cells [22] had similar expression pattern as Oct4 and
Figure 2. Dominant negative version of Sox3 promotes cell cycle exit. (A–C, J–L) Overexpression of Sox3-Myc in cells derived from grade IV
tumors, maintained cells in a proliferative, BrdU incorporating (A,J), Ki67 positive (B,K) and Nestin expressing (C,L) state. (D–F, J–L) Misxpression of the
dominant negative version of Sox3, Sox3EnR-Myc, caused cells to stop proliferating (D,E,J,K) and downregulate Nestin expression (F,L). eGFP
misexpression did not affect the rate of proliferation (G,H,J,K) or Nestin expression (I,L). Data are represented as mean +/2 SEM. *= p,0.05,
**= p,0.01, ***= p,0.001, Student’s t-test. Scale bar 20 mmi nI .
doi:10.1371/journal.pone.0018454.g002
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undifferentiated and self-renewing cells in high grade gliomas
express a combination of markers normally present in NSCs and
pluripotent stem cells. Teratomas have previously been shown to
express markers representative of pluripotent stem cells [23].
However, although we could detect a similar overlap in the
expression pattern of Sox2, Oct4 and Nanog in ES cell-derived
teratomas as in glioblastomas (Fig. S6), teratoma cells did not
express pluripotent stem cell markers in combination with NSC
proteins such as Sox1 (Fig. S6). To exclude a possible contribution
of non-transformed circulating stem cells to the population of cells
expressing Oct4 and Nanog we performed fluorescent in situ
hybridization (FISH) with probes recognizing the epidermal growth
factor receptor gene (EGFR), which is amplified in roughly 40% of
grade IV tumors [24]. Analysis of consecutive sections clearly
demonstrated Oct4 and Nanog expression in tumor cells with
EGFR gene amplification as well as in other tumor cells and other
tumor samples without EGFR gene amplification (Fig. S7).
Markers of all three germ-layers are represented in high
grade gliomas
It has previously been demonstrated that cells of high grade
gliomas are able to activate genetic programs leading to
mesenchymal transformation and the suppression of neuronal-
and glial-specific gene expression [25], but whether this finding
reflects a pluripotent potential of glioma cells remains unresolved.
To examine this possibility we analyzed tumor samples with an
array of mesodermal and endodermal markers. Interestingly, apart
from neural markers (Fig. 4A,B) many cells in grade IV tumors
had also activated gene expression representative of the mesoder-
mal lineage, including the brachyury homolog T [26], Dlx5 [27],
Snail1 [28] and Myogenin [29] (Fig. 4C,D,G; Fig. S8). In addition,
we could identify several endodermal lineage markers including
Sox17 [30,31,32], Gata6 [33] and FoxA2 [34] (Fig. 4E,F,H; Fig.
S8). Similar to the selective expression of Oct4 and Klf4 in high
grade gliomas, mesodermal and endodermal markers were
generally absent from grade II tumors (Fig. 4C,E,G,H). It is
important to point out that none of the examined tumors
expressed a full array of markers for mesodermal or endodermal
cells, and in most cases cells co-expressed genes characteristic of
different germ layers. For instance, T and Sox17 which define
mesodermal and endodermal lineages respectively, could often be
detected together with the NSC markers Sox1 and Nestin
(Fig. 4D,F; and Fig. S8). Nevertheless, our data indicate that gene
expression programs normally present in other than neural
lineages are induced in high grade gliomas.
Expression of pluripotent stem cell features depends on
environmental signals
To better understand how environmental signals may influence
the expression of stem cell properties, Sox2, Oct4 and Nanog
expression was measured in primary human glioblastoma cells
after intracranial engraftments, serial subcutaneous transplanta-
tions or in vitro culture. Resulting xenograft tumors, isolated two –
Figure 3. Increased malignancy is associated with the combined expression of Sox2, Oct4 and Nanog. (A–C) In tumors grade I-IV more
than 60% of the Sox2
+ cells express Nanog. (D) qPCR analyses demonstrate that Nanog mRNA can be detected in tumors of all grades. Values (fold
higher) normalized against grade I tumors. (E–G) While Oct4 is expressed at low levels in grade I-III tumors (E,G) Oct4 is expressed in more than 50%
of the Sox2
+ cells in grade IV tumors (F,G). (H) qPCR analyses demonstrate that Oct4 mRNA expression levels are significantly increased in grade IV
tumors in comparison with lower grade tumors. Values (fold higher) normalized against grade I tumors. The majority of cells expressing Nanog and
Oct4 are Ki67
+ (I,J) and Nestin
+ (K,L). Data are represented as mean +/2 SEM. **= p,0.01, ***= p,0.001, Student’s t-test. Scale bar 25 mm in J and
10 mmi nL .
doi:10.1371/journal.pone.0018454.g003
Pluripotent Stem Cell Traits in Human Glioblastoma
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e18454three months after intracranial transplantations in mice, contained
comparable amounts of Sox2
+, Oct4
+ and Nanog
+ cells as the
original human tumors (Fig. 5A–F and Fig. S9). Moreover, these
markers could be detected in tumors generated after serial
subcutaneous transplantations, and the number of Sox2
+ cells
expressing Oct4 and Nanog was essentially similar in primary and
quaternary xenograft tumors (Fig. 5G–L; and data not shown).
Glioma cells cultured in vitro initially expressed high levels of Sox2,
Oct4 and Nanog (LP; low passage) (Fig. 5M–O,V–X). However,
after a few passages their expression started to decline
(Fig. 5Q,R,W,X) and after prolonged propagation (.20 passages)
the expression of Oct4 and Nanog was generally lost
(Fig. 5T,U,W,X and Fig. S10). In contrast, Sox2 expression
remained unaltered and could be detected together with the NSC
marker Nestin for more than 35 passages (Fig. 5S–V; Fig. S10 and
data not shown). The expression of Oct4 and Nanog remained
decreased also in cells cultured in vitro as spheres rather than in
monolayer cultures (Fig. S11). Together, these data suggest that
while NSC genes remain unaltered in glioma cells cultured in vitro,
the expression of Oct4 and Nanog is dependent on extra-cellular
regulatory cues present in vivo but not in vitro. It has been suggested
that a hypoxic environment correlates with stem cells in
glioblastomas [35,36,37,38,39]. To examine whether exposure to
hypoxia increases the expression levels of stem cell markers we
cultured low and high passage glioblastoma cells in normoxia
(21% O2) and in hypoxia (1% O2). Although the cells exposed to
hypoxia exhibited a robust upregulation of the Hypoxia Inducible
Factor HIF1a, we could not detect any differences in Sox2, Oct4
or Nanog expression levels (Fig. S11). Neither could we detect any
significant spatial correlation between cells expressing stem cell
markers and neovascular niches as determined by the vasculature
markers CD31 and CD105 (endoglin) (Fig. S11).
Figure 4. Increased malignancy is characterized by the acquisition of pluripotent properties. (A,B) Cells expressing the neural progenitor
markers Pax6 and Nestin can be detected in both low (A) and high (B) grade glioma. (C–H) Expression of the mesodermal transcription factor T (C,D,G)
and the endodermal marker Sox17 (E,F,H) are restricted to grade IV tumors. Scale bar; 20 mm in F. Data are represented as mean +/2 SEM.
*= p,0.05, Student’s t-test.
doi:10.1371/journal.pone.0018454.g004
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That several of the malignant features of glioblastomas, including
aberrant growth, recurrence and radio-resistance, may be assigned
cancer stem cells, argues that this cellular population constitutes
a potential target for therapeutic strategies. However, to reach this
goal it is necessary that we understand the mechanisms that
promote stem cell maintenance in gliomas and endow cells with the
capacity to initiate and sustain tumor growth. In this study we have
demonstrated that glioblastomas express molecular similarities with
both NSCs and pluripotent stem cells. For instance, SoxB1 proteins
that in the healthy brain possess redundant and vital functions to
maintain NSCs in an undifferentiated and proliferative state [40]
are co-expressed in high grade gliomas but not in low grade. We
also demonstrated that Sox3 had similar effect in NSCs as in glioma
cells and and block cell cycle exit, whereas its dominant negative
version promote cell cycle exit in both NSCs and glioma cells. In
keeping with these findings, misexpression of Sox3 has previously
beendemonstrated tocauseoncogenictransformationofembryonic
fibroblasts [41] whereas microRNA-mediated suppression of Sox2
decreases the capacity of glioma cells to contribute to tumor growth
[8].Moreover, Sox3 wasidentifiedasa target of retroviral insertions
causing T-cell lymphomas in mice [42] and the Sox2 locus is
frequently amplified in prostate cancer [43]. Thus, several lines of
evidence indicate that SoxB1 proteins are significant in promoting
the undifferentiated state also in tumors.
Sox2, Oct4 and Nanog are vital for the development and
maintenance of pluripotent stem cells [44,45,46,47]. For instance,
all three proteins have been assigned prominent roles in
reprogramming somatic cells into iPS-cells [48] and loss of Nanog
or Oct4 in ES-cells leads to the suppression of pluripotent stem cell
features and transdifferentiation of ES-cells into extra-endodermal
cells and trophectodermal cells, respectively [14,44]. Moreover,
gain-of-function experiments have demonstrated a role of Nanog
Figure 5. Stem cell features of high grade gliomas are dependent on the cellular niche. (A–F) The expression of Sox2 (A), Oct4 (B) and
Nanog (C) was maintained in grade IV glioma cells subjected to intracranial engraftments in mice (D–F). The expression of Sox2 (G), Oct4 (H) and
Nanog (I) was also maintained in cells exposed to repeated rounds of serial subcutaneous transplantations. Expression is here shown in quaternary
(4u) tumors (J–L). (M–X) In vitro propagated tumor cells were examined for the expression of Sox2, Oct4 and Nanog protein expression, using
cytohistochemistry and western blot analyses, after less than 10 passages (low passage, LP), between 10–20 passages (medium passage, MP) or after
more than 20 passages (high passage, HP). While the expression of Sox2 was maintained for more than 50 passages (M,P,S,V) the expression of Oct4
(N,Q,T,W) and Nanog (O,R,U,X) declined after 10–20 passages. Quantification of three independent experiments show a significant loss of Oct4
(p,0.005) and Nanog (p,0.001) but not Sox2 (p.0.60) upon prolonged propagation, Student’s t-test (Fig. S10). The loss of Oct4 and Nanog
expression did not alter the expression of the neural progenitor marker Nestin (Q–R, T–U). In vitro studies and subcutaneous xenograft data are based
on three distinct tumor samples. Intracranial xenograft data represent an additional tumor sample. Scale bars; 20 mmi nC ,5 0mmi nF ,5 0mm in L and
10 mmi nU .
doi:10.1371/journal.pone.0018454.g005
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is interesting that co-expression of Sox2, Oct4 and Nanog
primarily could be detected in highly malignant forms of gliomas
and that downstream target genes of these transcription factors in
ES-cells, frequently are overexpressed in poorly differentiated
tumors including glioblastomas [16]. Thus, it is possible that the
transcription factors Sox2, Oct4 and Nanog that regulate self-
renewal and pluripotency of stem cells have similar regulatory
functions in gliomas. Indeed, suppression of Nanog expression in
glioma cells reduced their tumorgenicity when transplanted into
the mouse brain [50]For instance, their expression was accompa-
nied by the presence of markers characteristic for the mesodermal
or endodermal lineages. T protein, which is required for
mesoderm formations [26], is significantly expressed in glioma
tissue together with the muscle determination factor Myogenin
[29]. In addition, we could detect expression of the endodermal
regulators Sox17, Gata6 and FoxA2 [30,31,32,33]. Although some
of the endodermal and mesodermal proteins we identified,
previously have been detected in association with the vasculature
[51,52,53], the vast majority of the glioma cells expressing these
markers were not associated with blood vessels in the tumors
examined in this study. In contrast to neuronal and glial gene
expression we were unable to detect cells expressing a complete
array of mesodermal and endodermal markers. Instead, many cells
expressing endodermal and mesodermal genes also expressed the
neural progenitor cell markers Nestin and Sox1. Thus, rather than
reflecting the formation of cells of endodermal or mesodermal
lineages, it is conceivable that the mixed cellular phenotype in high
grade gliomas results from deregulated gene expression, perhaps
involving the activity of Sox2, Oct4 and Nanog.
One possible explanation for the differential expression of Sox1,
Oct4 and Klf4 in low and high grade tumors, is that these tumor
types may constitute distinct disease entities [54]. However, gene
expression in cancer cells is also largely dependent on signals in the
micro-environment. That signals in the micro-environment have
regulatory roles in controlling cancer cell gene expression, is in
agreement with our findings that cells isolated from high grade
tumors rapidly downregulated the expression of Oct4 when cultured
in vitro, while the expression was maintained in cells xenografted into
the mouse brain or serially transplanted subcutaneously into mice.
Thus, it is likely that regulators of pluripotency, such as Oct4, are
selectively expressed in high grade gliomas as a result of
a combinatorial activity of cell autonomous mechanisms and signals
emanating from the tumor microenvironment.
In this paper we have demonstrated that glioblastomas display
mixed characteristics of neural and pluripotent stem cells.
Although our results indicate that the capacity of Sox3 to hinder
differentiation is conserved between glioma cells and NSCs,
further studies will be necessary to explain the exact role of Oct4,
Nanog and Klf4 in gliomas. For instance, is their ability to
promote the self-renewing and undifferentiated state conserved in
gliomas and are they necessary for the pluripotent features
expressed by glioblastomas? Nevertheless, it is tempting to propose
that independently of the genetic alterations that may be present in
cancer cells, stem cell regulatory programs may constitute vital
targets for therapeutic innovations combating tumor growth.
Materials and Methods
Ethical statement and handling of human glioma
samples
Twenty-three snap frozen human glioma samples were used in
this work: 7 glioblastomas (WHO Grade IV), 6 WHO Grade III
cases (2 anaplastic astrocytomas and 4 anaplastic oligoastrocyto-
mas), 8 WHO Grade II cases (3 astrocytomas, 3 oligoastrocyto-
mas, 2 oligodendrogliomas) and 2 WHO Grade I cases (2 pilocytic
astrocytomas). Informed consent had been obtained from the
patients before surgery (KI 02-254) and diagnosis was confirmed
by a neuropathologist (AO). The snap frozen tissues used for
qPCR had the following distribution: 30 glioblastomas (WHO
Grade IV), 15 WHO Grade III cases (anaplastic astrocytomas), 19
WHO Grade II cases (astrocytomas) and 14 WHO Grade I cases
(pilocytic astrocytomas). The samples used for qPCR were
obtained according to the ethical guidelines approved by De-
partment of Neurology, School of Medicine, University of Sao
Paulo and by the Brazilian Health Ministry.
Quantitative RT-PCR
Total RNA was extracted from snap frozen glioma samples with
RNeasy Protect Mini Kit (Qiagen). First-strand cDNA was
prepared using Superscript III (Invitrogen). qPCR was performed
with SYBRgreen (Qiagen), using primers specific for human Oct4
and human Nanog. The housekeeping gene HPRT was used for
cDNA normalization.
Immunohistochemistry, immunofluorescence and in situ
hybridization
Human glioma tissues and serial xenografted tissues were fixed
in 4% paraformaldehyde (PFA) and embedded in paraffin. 5 mm
sections were de-paraffinized and processed with antigen retrieval
followed by antibody incubation at 4uC overnight. Stainings were
visualized by DAB-based HRP-reaction and counterstaining
performed with Haematoxylin. Snap frozen human tumor samples
were cryosectioned. The 12 mm sections were fixed in 4% PFA for
15 minutes at room temperature. Sections were incubated
overnight with primary antibodies at 4u Celsius. The antibodies
used were: rabbit anti-Sox1 (1/1000, kind gift from Dr Wilson,
Umea ˚ University), goat anti-Sox2 (1/1000), guinea-pig anti-Sox3
(1/2000), rabbit anti-Sox2 (1/2000) (kindly provided by T.
Edlund, Umea ˚ University), mouse anti-Nestin (1/1000, Millipore
Mab 5326), mouse anti-Ki67 (1/500, Abcam), rabbit anti-Ki67
(1/500, Neomarkers RB1510P0), rabbit anti-Neurofilament (1/
1000, Serotec AHP286), rabbit anti-Oct4 (1/250, Santa Cruz
sc9081), rabbit anti-Nanog (1/250, Abcam 21603), rabbit anti-
Pax6 (1/500, Developmental Hybridoma Bank), goat anti-
Brachyury (T) (1/250, Santa Cruz 17743), goat anti-Sox17 (1/
250, Neuromics Gt15094), anti-Gata6 (1/500, Santa Cruz
sc9055), mouse anti-FoxA2 (1/100, Developmental Hybridoma
Bank), mouse anti-cd31 (1/400, Abcam ab9498), mouse anti-
cd105 (1/400, DAKO M3527) and rabbit anti-Myogenin (1/250,
Santa Cruz sc576). Images of stained sections were acquired with
a Zeiss Axioplan Imager M1 mciroscope fitted with LSM5
confocal equipment. Images of cultured, fixed (4% PFA, 15 min,
RT) cells and stained cells were acquired with a Zeiss Observer Z1
fluorescence microscope. The images were processed with Adobe
Photoshop 4.0 software. In situ hybridization was performed as
described [55] with probes specific for human Sox1, Sox2 and Sox3.
FISH
FISH was performed on formaldehyde-fixed 12- mm cryosec-
tions from patient-derived snap-frozen tumor samples using Vysis
EGFR/CEP7 FISH probe Kit (Vysis, Abbott Laboratories)
according to the manufacturer’s protocol.
Induction of hypoxia
Low and high passage glioma cells seeded in 100-mm dishes
were incubated at 1% oxygen for 24 h in a Hypoxic Station
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Expression constructs and transfection
cDNAs were expressed in glioma cultures from the CMV-IE
enhancer/chick b-actin promoter in the pCAGGS vector [56].
cDNAs encoding Sox3-myc and Sox3-EnR have been described
elsewhere [9]. Expression vectors containing cDNAs encoding
human Sox1-myc, Sox2-myc, Sox3-myc, Oct4-myc and Nanog-myc were
obtained from Origene. DNA constructs were electroporated with
Neon (Invitrogen) or transfected with Mirus TransIT (Mirus) into
the cells.
Western blot
The protein levels of Sox2, Oct4 and Nanog in different
passages of glioma cells were assayed by Western blot. Cell lysates
were prepared using modified RIPA buffer supplied with
Protease Inhibitor Cocktail (Roche). Protein concentrations were
determined using the BIO-Rad Protein Assay (Bio-Rad). Samples
were separated in a 4–12% SDS-polyacrylamide gel (Invitrogen)
according to standard procedures and blotted onto a PVDF
membrane (Millipore). Immunoblotting was performed with
commercially available antibodies (anti-Sox2 antibody, Chemi-
con; anti-Oct4 antibody, sc-5279, Santa Cruz; anti-Nanog
antibody, eBioscience, anti-Hif1a, Bethyl A300-286A). ECL
(Amersham) was applied for chemiluminescence detection.
Immunoblotting signal quantifications were performed using
the AIDA software, version 3.10.039 (Raytest, Straubenhardt,
Germany)
Serial subcutaneous xenograft assay and human glioma
cell cultures
Human glioma tumor tissues were collected and pieces of the
tissues were mechanically dissociated in a sterile Petri dish with
a scalpel, followed by passage through syringe/needle with
diminishing diameter. Two ml of cold PBS was used to collect
the tumor tissue. A 0.6 mm needle was finally used to transfer
250 ml of minced tumor tissue subcutaneously to two SCID
(Severe Combined Immune Deficiency) mice. Time to the
development of visible tumor was registered. Tumor size was
measured and monitored daily. When tumor size reached
500 mm
3 the animals were sacrificed and tumors collected.
Xenograft tumor tissues were collected and prepared the same
way as original tissues, and applied for serial xenografts, (C207/1
Uppsala). At the time when the original human glioma tumor
tissues were collected, parallel cell cultures were established, either
maintained as monolayer with MEM media supplemented with
10% FBS or grown as spheres with neurosphere medium (#05751
Neurocult NA-S proliferation human kit; StemCell Technologies),
supplemented with 20 ng/ml of EGF (Invitrogen), 20 ng/ml
bFGF (Invitrogen) and 2 mg/ml Heparin (Sigma).
Intracranial transplantation
Human tumor tissue was mechanically dissociated as described
above. Depending on the amount of tumor tissue it was sometimes
necessary to elute this with 0.5 to 1 ml of PBS. A 0.6 mm needle
and Hamilton syringe with mechanical dispenser was finally used
to transfer 10 ml of minced tumor tissue intracranially to each
mouse. The injection was placed in the right frontal lobe of SCID
mice. After two months or as soon as the mice showed any signs of
illness, the animals were euthanized and brains were collected.
The brains were fixed in PFA (2%) and then embedded in
paraffin. Animal ethics committee approval no C159/98.
Human ES cell culture and teratoma formation
The fully characterized permanent human embryonic stem cell
(hESC) lines used as controls here, HS293 and HS346 have been
derived from fresh poor quality embryos that had been donated
for research after informed consent, and Karolinska Institutet
Ethics Board approval, in the Fertility Unit of the Karolinska
University Hospital, Huddinge, Sweden, as described earlier
[57,58]. They were derived using postnatal human skin fibroblasts
as feeder cells and Knockout Serum Replacement (SR, Invitrogen,
Scotland)-containing medium. For the present study, both lines
were cultured feeder-free on Matrigel (Becton & Dickinson, San
Jose, CA, USA) in mTeSR1 medium (StemCell Technologies,
Grenoble, France) in small chambers for immunocytochemistry.
The hESC lines have been karyotyped several times after
derivation, and they were found repeatedly to be cytogenetically
normal. After injection into testes of SCID mice, they have formed
benign teratomas containing differentiated tissue components of
the three germ layers. For teratoma formation, about 500,000
hESCs were harvested from culture plates, washed with PBS, and
subsequently implanted beneath the testicular capsule of 7-week-
old severe combined immunodeficiency (SCID/Beige) mice (C.B.-
17/Gbms Tac-scid-bgDF N7, N&M, Ry, Denmark). Teratoma
growth was determined by palpation every week, and the mice
were euthanized (cervical dislocation) 8 weeks after implantation.
The animals were housed in a specific pathogen-free facility of the
Karolinska University Hospital Huddinge, in accordance with the
ethics committee approval. The teratomas were fixed in formalin,
and sections stained with haematoxylin and eosin to identify
components of the germ layers. For the present study, sections for
immunohistochemistry were plated on polylysine-coated object
slides.
Supporting Information
Figure S1 Hematoxylin and eosin (H&E) analysis of
grade IV glioma. H&E characterizations demonstrate that the
Sox1 mRNA in situ hybridization signal (A) overlaps with
preserved tumor area in a grade IV sample with extensive necrotic
and hemorrhagic areas (B). Image (C) represents magnification of
framed regions in (A,B). Scale bars; 200 mmi nB ,2 0mmi nC .
(TIF)
Figure S2 Antibodies and in situ probes generated
against Sox1, -2 or -3 are specific for their respective
protein and mRNA. (A–I) Antibodies against Sox1, Sox2 or
Sox3 were used to stain 293HEK cells transfected with vectors
expressing Myc-tagged versions of human Sox1 (A–C), Sox2 (D–F)
or Sox3 (G–I). (J–L) Human embryonic stem cells express high
amounts of Sox2 (K), but not Sox1 (J) or Sox3 (L). (M) Human
Sox1, Sox2 or Sox3 cDNA was spotted onto Hybond-N
membranes (1 pg–100 pg). The membranes were hybridized with
DIG-labeled human Sox1, Sox2 or Sox3 RNA probes. Hybrid-
ization was detected with Nucleic Acid Detection kit for 1 hour.
Scale bar: 20 mmi nL .
(TIF)
Figure S3 Antibodies generated against Oct4 and Nanog
are specific for their respective protein. (A–D) Antibodies,
raised in mouse or rabbit, against Oct4 and Nanog were used to
stain 293HEK cells transfected with vectors expressing Myc-
tagged versions of human Oct4, (A,B) or Nanog (C,D). (E,F)
Human embryonic stem cells express high amounts of Oct4 (E)
and Nanog (F). (G,H) A substantial proportion of Tera2 human
Pluripotent Stem Cell Traits in Human Glioblastoma
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(TIF)
Figure S4 Glioblastoma tissue expresses Nanog and
Oct4. Hematoxylin and eosin analyses demonstrate that high
cellularity glioblastoma regions contain Nanog
+ (A,B) and Oct4
+
(C,D) cells. Scale bar: 20 mmi nD .
(TIF)
Figure S5 High level Klf4 expression is detected in high
grade glioma. The expression of Klf4 increased with increasing
grades of malignancy. The amount of Sox2
+ cells expressing Klf4
increased from approximately 17% in grade II tumors (A,C) to
above 50% in grade IV gliomas (B,C). Data are represented as
mean +/2 SEM. ***=p,0.001, Student’s t-test. Scale bar:
20 mmi nB .
(TIF)
Figure S6 Expression of pluripotent stem cell markers
in human teratoma cells. (A–E) In human ES derived
teratoma xenografts the expression of Oct4 (D) and Nanog (E) is
localized in areas with high Sox2 (B) expression but low Sox1 (A)
and Sox3 (C) expression. (F) H&E staining of the region depicted
in A–E (F). (G–J) Sox1 (G), Sox2 (H) and Sox3 (I) expression is
high in rosette-like neurogenic regions with high levels of nestin
(G) and tuj1 (H). These regions exhibit no expression of Oct4 (J) or
Nanog (K). (L) H&E staining of the region depicted in G–K (L).
Scale bar: 30 mmi nL .
(TIF)
Figure S7 Tumor cells expressing Oct4 and Nanog also
harbor EGFR amplification on chromosome 7. (A–F)
Serial sections from two representative grade IV tumors showing
(arrows in A, B) that the expression of Oct4 and Nanog is present
in tumor areas with EGFR amplification. EGFR gene copies (red)
are shown compared to the chromosome 7 specific probe (green)
in the same nuclei. Scale bars: 10 mm in D and F.
(TIF)
Figure S8 Mesodermal and endodermal markers pres-
ent in glioblastoma. (A–L) Grade IV tumors, but not grade II,
H&E staining in (A,B) express the mesodermal markers Dlx5
(C,D), Snail (E,F), Myogenin (G,H) and the endodermal markers
FoxA2 (I,J) and Gata6 (K,L). (M,N) Both the mesodermal marker
T (M) and the endodermal marker Sox17 (N) could be detected
together with the neural progenitor marker Sox1. Scale bar:
20 mmi nN .
(TIF)
Figure S9 Intracranially transplanted human glioma
cells retain Oct4 expression and hypercellularity. (A–C)
H&E staining showing human glioma cells growing in normal
mouse brain tissue (A). The boxed area is shown in higher
magnification in (B,C). Intense combined Oct4 and Nestin staining
is evident in the transplanted glioma cells but not in the
surrounding tissue (C). Scale bar: 60 mmi nC .
(TIF)
Figure S10 Grade IV glioma cells exhibit progressive
loss of Oct4 and Nanog but maintain Sox2 expression
upon prolonged in vitro propagation. (A–C) Sox2 protein
levels are not significantly altered over repeated passages (A),
whereas the levels of Oct 4 (B) and Nanog (C) protein are
significantly lower after prolonged propagation. Data are repre-
sented as mean +/2 SEM. **=p,0.01, ***=p,0.001, Student’s
t-test, n=3 for each condition and each marker.
(TIF)
Figure S11 Expression of Sox2, Oct4 and Nanog in
tumors is not restricted to the vascular niche. Sox2, Oct4
and Nanog expression is not induced by hypoxia or by
growing late passage cells as spheres. (A–C) Low passage
cells grown as gliospheres express Sox2 (A), Oct4 (B), Nanog (C)
and Nestin (A–C). (D–F) High passage cells maintain Sox2 (D) and
Nestin (D–F) expression but do not express Oct4 (E) or Nanog (F).
(G) The change from normoxic conditions (21%) to hypoxic
conditions (1%) robustly induces Hif1a expression but does not
affect expression levels of Sox2, Oct4 or Nanog neither in cells
from low passage nor in high passage cells. (H–M) Serial sections
(H–J, K–M) from primary GBM tumors showing that expression
of Sox2, Oct4 and Nanog is not restricted to the vascular niche as
outlined by the expression of CD31 (H–J) and CD105 (K–M).
Scale bars: 50 mm in F and 60 mmi nM .
(TIF)
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